IP Library Granted Patent US 8,084,475
Granted Patent B2
US 8,084,475 · App. 12/684,543 · Granted Dec 27, 2011

Pirfenidone therapy and inducers of cytochrome P450

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,475
App. No.
12/684,543
Granted
Dec 27, 2011
Kind
B2
Abstract

The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.

Claims (11)

1. A method of administering pirfenidone therapy to a patient in need thereof, wherein said patient is also in need of a strong inducer of CYP1A2 other than cigarette smoke, comprising (a) administering to the patient a therapeutically effective amount of pirfenidone and (b) avoiding concomitant administration of said strong inducer of CYP1A2.

2. The method of claim 1 , wherein the patient has idiopathic pulmonary fibrosis (IPF).

3. The method of claim 1 , wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day.

4. A method of administering pirfenidone therapy to a patient in need thereof, wherein said patient is receiving a strong inducer of CYP1A2 other than cigarette smoke, comprising (a) first discontinuing administration of the strong inducer of CYP1A2, and then (b) administering to the patient a therapeutically effective amount of pirfenidone.

5. The method of claim 4 , wherein the patient discontinues administration of said strong inducer of CYP1A2 concurrent to administration of pirfenidone.

6. The method of claim 4 , wherein the patient has idiopathic pulmonary fibrosis (IPF).

7. The method of claim 4 , wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day.

8. A method of increasing the effectiveness of pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF) in a patient that is receiving a CYP1A2 inducer, comprising discontinuing the CYP1A2 inducer within 4 weeks prior to pirfenidone administration to decrease the levels of CYP1A2 induction, and then administering pirfenidone.

9. The method of claim 8 , wherein the amount of pirfenidone is administered at a daily dosage of 2400 mg or 2403 mg per day.

10. The method of claim 8 , wherein the patient is a current smoker and smoking is discontinued within 4 weeks prior to pirfenidone administration.

11. The method of claim 10 , wherein the pirfenidone is administered at a daily dosage of 2400 mg or 2403 mg per day.

Assignments (4)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2025
From: INTERMUNE, INC.
To: LEGACY PHARMA INC. SEZC
Reel/Frame 070877/0547 →
CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS Recorded Jul 27, 2018
From: INTERMUNE, INC.
To: INTERMUNE, INC.
Reel/Frame 046638/0466 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2010
From: BRADFORD, WILLIAMSON ZIEGLER; SZWARCBERG, JAVIER
To: INTERMUNE, INC.
Reel/Frame 023763/0309 →